InvestorsHub Logo
Followers 137
Posts 22812
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Tuesday, 10/27/2020 9:26:48 PM

Tuesday, October 27, 2020 9:26:48 PM

Post# of 457732
extremely encouraging data.

“As the first double-blind trial of ANAVEX®2-73 (blarcamesine) in PDD, this proof-of-concept study provides extremely encouraging data. PDD can be debilitating with significant co-morbidities. New therapies are urgently needed to alleviate this suffering and disability. There has not been a mechanistically novel medication approved for PDD in over 20 years.”



https://www.globenewswire.com/news-release/2020/10/15/2109061/0/en/Anavex-Life-Sciences-Announces-Positive-Results-from-Proof-of-Concept-controlled-Phase-2-Clinical-Trial-Evaluating-ANAVEX-2-73-blarcamesine-in-Parkinson-s-Disease-Dementia.html

Good luck and GOD bless.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News